A carregar...

Management of tyrosine kinase inhibitor resistance in lung cancer with EGFR mutation

The identification of driver mutations and drugs that inhibit their activity has been a major therapeutic advance for patients with advanced lung adenocarcinoma. Unfortunately, the success of these drugs is limited by the universal development of resistance. Treatment failure can result from inadequ...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Becker, Kevin, Xu, Yiqing
Formato: Artigo
Idioma:Inglês
Publicado em: Baishideng Publishing Group Inc 2014
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4129521/
https://ncbi.nlm.nih.gov/pubmed/25302160
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5306/wjco.v5.i4.560
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!